Previous 10 | Next 10 |
DENVER, Colo., July 16, 2020- Today’s biotech headlines include developments from Emmaus Life Sciences, Inc. (OTCQB:EMMA), AC Immune SA (NASDAQ:ACIU), and Nabriva Therapeutics plc (NASDAQ:NBRV). Emmaus Life Sciences, Inc. (OTCQB:EMMA), a leader in sickle cell disease treatment, announced ...
Gainers: InnerWorkings (NASDAQ: INWK ) +117% . More news on: InnerWorkings, Inc., Heat Biologics, Inc., Boxlight Corporation, Stocks on the move, , Read more ...
AC Immune (NASDAQ: ACIU ) +76% on advancement of Alzheimer's vaccine study. More news on: AC Immune SA, Future FinTech Group Inc., Boxlight Corporation, Stocks on the move, , Read more ...
Thinly traded small cap AC Immune (NASDAQ: ACIU ) jumps 92% premarket in reaction to its announcement that it has initiated the medium dose cohort in its 24-subject Phase 1b/2a clinical trial evaluating Alzheimer's disease (AD) anti-Tau vaccine candidate ACI-35.030 in ...
Interim data confirm the promising safety, tolerability and Tau-specific immunogenicity observed in the previous clinical study ACI-35.030 is a clinical stage vaccine generated with the proprietary SupraAntigen ™ platform addressing proteinopathies across neurodegenerative dise...
BERLIN and LAUSANNE, Switzerland, July 07, 2020 (GLOBE NEWSWIRE) -- Life Molecular Imaging and AC Immune SA (NASDAQ: ACIU) announce the publication of clinical data of the investigational Tau-positron emission tomography (PET) tracer PI-2620 in patients with progressive supranuclear palsy (...
LAUSANNE, Switzerland, June 26, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, announced AC Immune shareholders approved all of the resolutions as proposed by the Boar...
The following slide deck was published by AC Immune SA in conjunction with this Read more ...
LAUSANNE, Switzerland, May 15, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will showcase key programs focused on novel targets in neurodegen...
AC Immune (NASDAQ: ACIU ): Q1 Non-GAAP EPS of -CHF0.09 beats by CHF0.05 ; GAAP EPS of -CHF0.11 beats by CHF0.03 . More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...
2024-05-30 18:00:07 ET Thomas Shrader from BTIG issued a price target of $8.00 for ACIU on 2024-05-30 16:49:00. The adjusted price target was set to $8.00. At the time of the announcement, ACIU was trading at $3.97. The overall price target consensus is at $10.00 with hi...